These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15110876)

  • 1. A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer.
    Baaten G; Voogd AC; Wagstaff J
    Eur J Cancer; 2004 May; 40(8):1127-44. PubMed ID: 15110876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.
    Dutcher JP
    Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):4-10. PubMed ID: 12469934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferon.
    Han KR; Pantuck AJ; Belldegrun AS
    Curr Urol Rep; 2002 Feb; 3(1):11-2. PubMed ID: 12084213
    [No Abstract]   [Full Text] [Related]  

  • 4. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
    J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
    Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What to do with IL-2?
    Dillman RO
    Cancer Biother Radiopharm; 1999 Dec; 14(6):423-34. PubMed ID: 10850329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
    Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
    Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09.
    Dillman RO; Wiemann MC; Tai DF; Depriest CB; Soori G; Stark JJ; Mahdavi K; Church CK
    Cancer Biother Radiopharm; 2006 Apr; 21(2):130-7. PubMed ID: 16706633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
    Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
    Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
    Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
    Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldesleukin in advanced renal cell carcinoma.
    Schmidinger M; Hejna M; Zielinski CC
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):957-80. PubMed ID: 15606326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
    McDermott DF; Regan MM; Atkins MB
    Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.
    Ellerhorst JA; Sella A; Amato RJ; Tu SM; Millikan RE; Finn LD; Banks M; Logothetis CJ
    Cancer; 1997 Dec; 80(11):2128-32. PubMed ID: 9392335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma.
    Atzpodien J; Hoffmann R; Franzke M; Stief C; Wandert T; Reitz M
    Cancer; 2002 Sep; 95(5):1045-50. PubMed ID: 12209689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: a phase II trial of the National Biotherapy Study Group.
    Dillman RO; Wiemann MC; Bury MJ; Church C; DePriest C
    Cancer Biother Radiopharm; 1997 Feb; 12(1):5-11. PubMed ID: 10851441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma.
    Geertsen PF; Gore ME; Negrier S; Tourani JM; von der Maase H
    Br J Cancer; 2004 Mar; 90(6):1156-62. PubMed ID: 15026795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
    Shulman KL; Stadler WM; Vogelzang NJ
    Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
    J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.